多发性骨髓瘤
医学
双特异性抗体
肿瘤科
临床试验
抗体
癌症研究
内科学
单克隆抗体
免疫学
作者
Zachary M. Avigan,Mohammad Rattu,Joshua Richter
标识
DOI:10.1080/14712598.2025.2465825
摘要
Linvoseltamab has a similar efficacy profile with favorable CRS incidence and time-to-onset compared to other approved bispecific antibodies. Pending final regulatory approval and labeling, further real-world analyses are needed to evaluate its final role in the evolving landscape of T cell redirection therapy for MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI